Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roni Mamluk

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Advances in Experimental Medicine and Biology|March 5, 2003
The role of neuropilin in vascular and tumor biologyMichael Klagsbrun, Seiji Takashima, Roni Mamluk
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 14, 2004
VEGF is required for the maintenance of dorsal root ganglia blood vessels but not neurons during developmentMatthew E Kutcher, Michael Klagsbrun, Roni Mamluk
Angiogenesis|December 6, 2005
Soluble neuropilin targeted to the skin inhibits vascular permeabilityRoni Mamluk, Michael Klagsbrun, Michael Detmar, et al.
The Journal of Biological Chemistry|May 3, 2002
Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domainRoni Mamluk, Ze'ev Gechtman, Matthew E Kutcher, et al.
Development (Cambridge, England)|April 10, 2004
VEGFA is necessary for chondrocyte survival during bone developmentElazar Zelzer, Roni Mamluk, Napoleone Ferrara, et al.
Pathology|July 1, 2014
Regulation of soluble neuropilin 1, an endogenous angiogenesis inhibitor, in liver development and regenerationDipak Panigrahy, Irit Adini, Roni Mamluk, et al.
Pharmaceutical Research|February 22, 2014
A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanismsShmuel Tuvia, Dori Pelled, Karen Marom, et al.
Developmental Biology|March 6, 2003
Neurovascular congruence results from a shared patterning mechanism that utilizes Semaphorin3A and Neuropilin-1Damien Bates, G Ian Taylor, Joe Minichiello, et al.
BMC Cancer|November 29, 2008
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancerSean P Dineen, Laura A Sullivan, Adam W Beck, et al.
Cancer Cell|March 16, 2005
Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatinRonit Satchi-Fainaro, Roni Mamluk, Ling Wang, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Advances in Experimental Medicine and Biology|March 5, 2003
The role of neuropilin in vascular and tumor biologyMichael Klagsbrun, Seiji Takashima, Roni Mamluk
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 14, 2004
VEGF is required for the maintenance of dorsal root ganglia blood vessels but not neurons during developmentMatthew E Kutcher, Michael Klagsbrun, Roni Mamluk
Angiogenesis|December 6, 2005
Soluble neuropilin targeted to the skin inhibits vascular permeabilityRoni Mamluk, Michael Klagsbrun, Michael Detmar, et al.
The Journal of Biological Chemistry|May 3, 2002
Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domainRoni Mamluk, Ze'ev Gechtman, Matthew E Kutcher, et al.
Development (Cambridge, England)|April 10, 2004
VEGFA is necessary for chondrocyte survival during bone developmentElazar Zelzer, Roni Mamluk, Napoleone Ferrara, et al.
Pathology|July 1, 2014
Regulation of soluble neuropilin 1, an endogenous angiogenesis inhibitor, in liver development and regenerationDipak Panigrahy, Irit Adini, Roni Mamluk, et al.
Pharmaceutical Research|February 22, 2014
A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanismsShmuel Tuvia, Dori Pelled, Karen Marom, et al.
Developmental Biology|March 6, 2003
Neurovascular congruence results from a shared patterning mechanism that utilizes Semaphorin3A and Neuropilin-1Damien Bates, G Ian Taylor, Joe Minichiello, et al.
BMC Cancer|November 29, 2008
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancerSean P Dineen, Laura A Sullivan, Adam W Beck, et al.
Cancer Cell|March 16, 2005
Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatinRonit Satchi-Fainaro, Roni Mamluk, Ling Wang, et al.
Pageof 2